# Shattuck Labs, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Shattuck Labs, Inc.). ## Overview Shattuck Labs is a U.S.-based clinical-stage biotechnology company focused on discovering and developing antibody-based therapies for immune-mediated diseases. The company’s pipeline has centered on programs such as SL-325 and earlier candidates, with research, development, and clinical operations conducted from its U.S. offices in Austin, Texas and Durham, North Carolina. ## Products & services • SL-325 and other antibody drug candidates • Discovery and preclinical research programs • Clinical development for immune-mediated diseases • Collaboration and licensing arrangements • Process development and outsourced manufacturing support - **Clinical-stage drug candidates** (70%) — Antibody-based therapeutic programs being advanced through preclinical and clinical development. - **Collaboration and license revenue** (20%) — Revenue from research, licensing, and collaboration agreements with third parties. - **Discovery and translational research** (10%) — Internal research activities that generate new therapeutic candidates and platform insights. - SL-325 and other antibody drug candidates - Discovery and preclinical research programs - Clinical development for immune-mediated diseases - Collaboration and licensing arrangements - Process development and outsourced manufacturing support ## Customers Shattuck Labs does not sell approved commercial products; its economic counterparties are pharmaceutical and biotechnology partners, research collaborators, and potential future licensing or development partners. Its programs are aimed at patients with immune-mediated diseases, while current revenue is tied to collaboration and license agreements rather than product sales. - **Pharmaceutical and biotechnology collaborators** (primary) — Partners that enter research, option, or license agreements around Shattuck’s antibody programs and platform assets. - **Clinical development partners** (secondary) — Organizations that may support or co-develop later-stage trials, manufacturing, or commercialization. - **Patients with immune-mediated diseases** (primary) — The eventual end users of approved therapies targeting inflammatory and immune-mediated conditions. - Pharma and biotech partners that license or collaborate on programs - Research collaborators funding discovery and development work - Future clinical and commercial partners for immune-disease assets - Patients with immune-mediated diseases as the ultimate end market ## Geography Shattuck Labs is headquartered and operates in the United States, with corporate offices in Austin, Texas and Durham, North Carolina. Its research and development footprint is U.S.-based, while clinical and manufacturing activities are outsourced to third-party organizations that may operate in multiple jurisdictions. - Headquartered in the United States - Corporate offices in Austin, Texas and Durham, North Carolina - U.S.-based employees and research operations - Clinical trials and manufacturing are outsourced to third parties - No disclosed country-level revenue concentration ## Strategy The company’s strategy is to advance antibody programs for immune-mediated diseases, with emphasis on clinical development of SL-325 and related pipeline assets. It also seeks to balance internal scientific capability with outsourced clinical research and manufacturing, while preserving flexibility to fund development through collaborations and capital raises. - **Advance SL-325 into later-stage development** (short-term) — Clinical progress is the main value driver for a company without commercial products. - **Strengthen internal development capabilities** (medium-term) — More in-house expertise can improve execution in research, process development, and clinical operations. - **Use partnerships to extend capital runway and broaden reach** (medium-term) — Collaborations can provide non-dilutive funding and external validation of the platform. - Advance SL-325 through regulatory and clinical milestones - Build expertise in clinical research, process development, and manufacturing - Use outsourced CRO and CMO partners to scale efficiently - Pursue collaboration and licensing opportunities to support funding - Maintain optionality across multiple immune-mediated disease programs ## Risks Shattuck Labs faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory approval risk, and dependence on external funding before any commercial product exists. Its business also depends on third-party CROs and contract manufacturers, making execution, supply, and quality control important sources of risk. - **Clinical development failure** [critical] — Product candidates may not show sufficient safety or efficacy in trials. - **Capital dependence** [high] — The company has no commercial product revenue and must fund long development cycles. - **Third-party manufacturing and trial execution** [high] — CROs and contract manufacturers control key parts of development and supply. - **Competitive pressure** [medium] — Larger companies and other clinical-stage peers are pursuing similar immune targets. - **Intellectual property protection** [high] — Patent coverage is needed to protect candidate molecules, methods, and formulations. - No approved products, so value depends on clinical and regulatory success - Needs additional capital to fund development and operations - Third-party CRO/CMO dependence can delay trials or supply - Competition from larger biotech and pharma companies is intense - Patent and IP protection are critical to defend the pipeline ## Accounting The most important accounting judgments are revenue recognition for collaboration agreements, accruals for research and development costs, and stock-based compensation. Because revenue is driven by milestone- and contract-based arrangements rather than product sales, timing of recognition can materially affect quarterly results, while R&D accruals depend on estimates for outsourced trial and manufacturing work. - **Revenue recognition for collaboration agreements** — Affects reported quarterly and annual revenue - **Accrued research and development expenses** — Affects operating expenses and liabilities - **Stock-based compensation** — Affects operating expense and dilution analysis - Collaboration revenue timing depends on contract obligations and milestones - Accrued R&D costs reflect estimates for CRO and CMO invoices - Stock-based compensation requires valuation assumptions and expense estimates - Quarterly revenue can be lumpy because it depends on agreement timing - Emerging growth company status can affect accounting standard adoption timing --- *Last updated: 2026-04-29T04:58:21.751562+00:00*